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Abstract Binding of the c~-granular thrombospondin (TSP) to 
the plasma membrane of activated platelets has long been docu- 
mented, yet the molecular mechanism involved in its secretion and 
surface expression have not been elucidated. Using a ligand blot 
binding assay where electrophoretically separated platelet pro- 
teins were incubated with purified 12Sl-labeled TSP, we observed 
a strong interaction of ['2SlITSP with a I00 kDa single chain 
protein. On performing a platelet subfractionation, the I00 kDa 
protein was predominantly localized in the cytosol from which it 
was purified by preparative lectrophoresis and was identified by 
amino acid sequencing to the cytoskeletal protein, a-actinin. We 
further demonstrated that ['2Sl]TSP interacts with a-actinin in a 
specific manner and with a high affinity (Kd = 6.6 nM) in a 
solid-phase binding assay. 
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1. Introduction 
Thrombospondin-I  (TSP) is a 420 kDa adhesive multifunc- 
tional glycoprotein which is synthesized and secreted by a large 
variety of cells and may interact with many molecules, such as 
heparin, heparan sulfate proteoglycans, ulfated glycolipids, 
collagens, fibronectin, laminin, fibrinogen and plasminogen [1- 
3]. Depending on the cellular types, potential receptors for TSP 
include proteoglycans [4], CD36 (also named glycoprotein 
(GP)IV or GPII Ib, in platelets) [5,6] and the integrins of the f13 
family: ~J,t, fl3 and 0~V~ 3 [7,8]. Three distinct receptors for TSP 
have also been identified on different umor cell lines [9-11]. 
Due to these multiple interactions, the expression of TSP on cell 
surfaces has been related to a number of processes uch as cell 
adhesion, migration and proliferation as well as cell-cell inter- 
actions [1-3]. In addition, TSP has been shown to play a role 
in platelet aggregation and fibrin clot formation [1-3] and is 
considered as a potential regulator of fibrinolysis [12] and angi- 
ogenesis [3]. However, the precise molecular mechanisms un- 
derlying the various biological functions of TSP are not clearly 
defined. An additional level of complexity was recently intro- 
duced with the identification of five structurally and genetically 
distinct forms of TSPs exhibiting different issue distribution 
*Corresponding author. Fax: (33) (1) 42 49 07 33. 
and potentially different functions [13]. To date, most studies 
concerned with biological functions have been conducted with 
platelet TSE now referred to as TSP-I. 
In platelets, TSP is secreted from a-granules and plays a 
major role in platelet aggregation by promoting the formation 
of irreversible platelet macroaggregates [14 16]. This effect is 
thought o be mediated by its binding to cell surface-associated 
fibrinogen and subsequent stabilization of the interaction of 
fibrinogen with its platelet receptor, the GPI Ib- I I Ia  complex 
or ~nbfl3 integrin [1,~17]. Integral membrane glycoproteins, 
including (3~11b]~ 3 itself, C~vfl3 and GPIV, are also considered as 
potential receptors for secreted TSP on activated platelets [5 8]. 
However, none of these molecules appear to be essential, as 
platelets from thrombasthenic patients that lack ~nbfl3 and 
~Xvfl3 or those from individuals lacking GPIV bind TSP 
normally [18 21]. Other studies have suggested that binding of 
c~-granular p oteins on the surface of activated platelets might 
arise from the secretion of these proteins already bound to 
endogenous receptors [22,23]. Thus, intracellular TSP binding 
molecules, to date unidentified, might also contribute to the 
surface expression of endogenous TSP on activated platelets. 
In this study, we have used a ligand blot binding assay com- 
bined with a platelet subfractionation to identify platelet com- 
ponents able to interact with purified ~25I-labeled TSR We 
report on the identification of the cytoskeletal actin binding 
protein, a-actinin, as a specific TSP binding protein. 
2. Materials and methods 
2.1. Platelet isolation and subJractionation 
Fresh human platelets were isolated from acid-citrate-anticoagulated 
blood, as described elsewhere [20]. Subcellular f actions were prepared 
according to previous procedures [24,25], with some modifications. 
Washed platelets were resuspended at 2 x 10 ~ cells/ml in 15 mM Tris- 
HC1, 1 mM ethylenediaminetetraacetic id (EDTA), 250 mM sucrose, 
0.2 mM leupeptin, 1 mM benzamidine, 100 nM prostaglandin E~ 
(Sigma Chemical Co., St. Louis, MO) and 25 ,ug/ml apyrase (grade l; 
Sigma), pH 7.4. The cells were disrupted on ice by controlled sonica- 
tion: 3 cycles of 5 s at 40 W with 1 min intervals (Vibra cell Sonifier; 
Bioblock Scientific, Illkirch, France) and centrifuged for 15 min at 
1,200 x g and 4°C. The pellet of unlysed platelets was resuspended and 
resonicated. After centrifugation, the two supernatants were combined. 
which comprised more than 90% of the platelet proteins, and centri- 
fuged for 30 rain at 19,000 x g and 4°C to isolate a crude organelle 
fraction. The supernatant was further centrifuged for 60 min at 
100,000 x g and 4°C to separate a crude membrane fraction from the 
cytosolic fraction. Organelle and membrane fractions were washed 
once by centrifugation asdescribed for their isolation. The purity of 
each platelet subfraction was assessed by measurements of 5-hy- 
droxytryptamine [26]. fl-thromboglobulin (Radioimmunoassay kit: 
0014-5793/95/$9.50 ~;) 1995 Federation of European Biochemical Societies. All rights reserved. 
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Amersham, Les Ulis, France), fl-glucuronidase [27], lactate dehydroge- 
nase [28] and adenylate cyclase activities [29], the respective markers of 
platelet dense bodies, c~-granules, lysosomes, cytosol and plasma mem- 
brane. 
2.2. Eleetrophoresis procedures 
Discontinuous SDS-PAGE was carried out on polyacrylamide slab 
gels, as described elsewhere [20], and two-dimensional electrophoresis 
was performed according to the procedure of O'Farrell, modified as 
described [30]. All reagents for electrophoresis were purchased from 
Bio-Rad (Richmond, CA). 
2.3. Demonstration f a TSP binding protein 
A TSP binding protein of 100 kDa was demonstrated in platelets by 
a ligand blot binding assay. Platelet proteins were separated by SDS- 
PAGE and electrotransferred to nitrocellulose sheets as previously de- 
scribed [20], except hat electrotransfer was carried out using a Semi- 
Phor semi-dry Transfer Unit (Hoefer Scientific Instruments, San Fran- 
cisco, CA). The nitrocellulose sheet was probed with [t25I]TSP (=0.3 
/tCi/ml, =2 3 ,ug/ml) in 15 mM Tris-HCl, 150 mM NaCI, 2 mM CaC12, 
2 mM MgCI2, 0.04% (w/v) Ficol1400 and 0.1% (v/v) Tween 20, pH 7.4, 
containing 1.5% (w/v) bovine serum albumin (BSA, fraction V; 
Boehringer-Mannheim, Germany) for 2 h at 20 °C. 
2.4. Purification and identification of the TSP binding prote#l 
The TSP binding protein found to be enriched in platelet cytosol was 
purified by preparative electrophoresis from this fraction. Platelet pro- 
teins (5 mg) from the platelet cytosolic fraction were separated by 
SDS-PAGE on a 6.5% polyacrylamide 3 mm-thick slab gel. The gel was 
immersed in a 4 M solution of sodium acetate for a rapid visualization 
of the protein bands [31] and the band at 100 kDa corresponding to the 
electrophoretic migration of the TSP binding protein was marked with 
a scalpel. The gel was extensively washed with 2.5% (w/v) Triton X-100 
(BDH Chemicals Ltd., Poole, England) to remove sodium acetate and 
SDS, and equilibrated in 10 mM Tris-HC1, pH 6.8. The 100 kDa protein 
band was cut out from the gel, crushed and left overnight at 4°C into 
10 mM Tris-HC1, pH 6.8. The eluted protein (= 100,ug) was recovered 
after centrifugation f the sample for 15 min at 12,000 x g and 4°C, and 
lyophilized. 
For identification of the TSP binding protein byamino acid sequenc- 
ing, peptides were generated from the purified protein by overnight 
digestion with trypsin (1:60, w/w; Boehringer-Mannheim) at 37°C. The 
material was lyophilized, solubilized in 200 ,ul 6 M guanidinium chlo- 
ride and injected onto a 218TP52 Vydac (Hesperia, CA) HPLC reverse- 
phase C,8 column. The peptides were eluted with 0.1% trifluoroacetic 
acid in water then with a 0 35% linear gradient of 0.1% trifluoroacetic 
acid in acetonitrile at a flow rate of 200/.fl/ml. Fractions were sequenced 
using an ABI 477 A sequencer with an on-line 120 A analyser (Applied 
Biosystems, Foster City, CA) and compared to sequences of the pro- 
teins contained in the Swiss-Prot protein data bank, using the Intelli- 
genetics Inc. omputer software. 
2.5. Solid-phase binding assays 
Solid-phase binding assays were performed as previously described 
[15] in microtiter wells coated in duplicate with 10 ,ug/ml purified c~- 
actinin, diluted in 20 mM Tris-HCl, 150 mM NaC1, 2 mM CaCI 2, pH 
7.2. BSA-coated wells were used as controls. Increasing concentrations 
of purified [J25I]TSP were incubated with c~-actinin or BSA-coated wells 
for 60 min at 37°C. Non-specific binding of [~251]TSP was determined 
as the residual binding measured in the presence of a 60-fold excess of 
unlabeled TSP. Purified fibrinogen (IMCO Corporation, Stockholm, 
Sweden) and fibronectin (Boehringer-Mannheim) were radiolabeled 
similarly to TSP and used in separate samples. 
3. Results 
3.1. Evidence for a specific association of  z:51-TSP with a 100 
kDa platelet protein 
When incubated with electrophoretically separated proteins 
from a platelet lysate in a blot binding assay (Fig. 1), []25I]TSP 
exhibited a strong reactivity with a component of an apparent 
molecular mass of 100 kDa (Fig. IA), the mobil ity of which did 
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Fig. 1. Specific interaction of [125I]TSP with a 100 kDa platelet protein by a blot binding assay. Proteins t¥om total platelet lysates were separated 
by SDS-PAGE, under non-reduced conditions, using an 8% polyacrylamide g l (A) or a 5 12% gradient polyacrylamide g l (B), electrotransferred 
to nitrocellulose sheets and incubated with 3 ,ug/ml [~251]TSP, as described in section 2. Bound radioactivity was visualized by autoradiography. 
(A) Decreasing amounts of platelet proteins were probed with [125I]TSP. (B) Platelet proteins (30/~g) were probed with ['~5I]TSP in the presence of 
2 mM CaCI2 and 1 mM MgC12, as in A, or 2 mM EDTA, as indicated in the figure. 
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Fig. 2. Subcellular f actionation showing the localization of the TSP binding protein in the platelet cytosol. Proteins (30#g) t¥om total platelet lysates 
or the different subfractions were electrophoresed on a 8% polyacrylamide g l under reduced conditions. (A) Proteins were stained by Coomassie 
blue: intact platelets (lane 1), platelet homogenate (lane 2), residual pellet from sonicated platelets (lane 3), gr ular fraction (19,000 x g pellet) (lane 
4), cytosolic fraction (100,000 x g supernatant) (lane 5), membrane fraction (100,000 x g pellet) (lane 6). (B) Proteins were electrotransferred and 
incubated with 2 #g/ml [~25I]TSP: platelet homogenate (lane 1), supernatant (lane 2) and granular f action (lane 3)from the 19,000 × g centrifugation, 
washed granular traction (lane 4), cytosolic fraction (lane 5), membrane fraction (lane 6), washed membrane lYaction (lane 7). 
not change upon disulfide reduction (see Fig. 2B). This protein 
did not correspond in size to any of the proteins o far identified 
as TSP binding molecules in platelets. By comparison, fibrino- 
gen, which is one of the most abundant proteins in platelets, 
exhibited a lower reactivity with ['25I]TSP. Similar results were 
obtained when the blots were incubated with unlabeled TSP 
followed by a radiolabeled anti-TSP antibody (not shown), 
clearly demonstrating that TSP, and not a possible minor con- 
taminant in the purified preparation, was actually interacting 
with the 100 kDa protein. The interaction of [125I]TSP with the 
100 kDa protein appeared to be very strong as it was detected 
even when as little as 7.5 #g of platelet proteins was probed 
(Fig. 1A) and was divalent cation-dependent as no significant 
binding occurred in the presence of 2 mM EDTA (Fig. 1B). 
3.2. Subcellular localization of the TSP binding protein 
To investigate the cellular localization of the 100 kDa pro- 
tein, a platelet subfractionation procedure was performed. The 
organelle fraction obtained, containing s- ranules, dense bod- 
ies and lysosomes, was enriched 2 3 fold infl-thromboglobulin, 
5-hydroxytryptamine and fl-glucuronidase r lative to the ho- 
mogenate. The cytosolic and membrane fractions were en- 
riched 2- and 10 fold, respectively, in lactate dehydrogenase and 
adenylate cyclase. When equal amounts of protein from these 
subfractions (Fig. 2A) were probed with [~:5I]TSP in the blot 
binding assay (Fig. 2B), the 100 kDa component was predom- 
inantly found in the cytosolic fraction (lane 5) comprising ap- 
proximately 50% of the total platelet proteins. A residual label- 
ing was associated with the washed organelle and membrane 
fractions (lanes 4 and 7) which contained approximately 20% 
and 10% of the platelet proteins, respectively. By counting the 
radioactivity associated with the 100 kDa band, we estimated 
that about 68%, 10% and 7% of the 100 kDa protein was 
recovered in the cytosolic, organelle and membrane fractions, 
respectively. 
3.3. Identification of the TSP binding protein to ~-actinin 
The 100 kDa protein was purified from the cytosolic fraction 
by preparative electrophoresis. Analysis by the O'Farrell two- 
dimensional electrophoresis procedure indicated the presence 
of a single protein with a series of charged isoforms 
(5.7 < pI < 6.2) (Fig. 3A and B), all of which reacted with 
[125I]TSP (Fig. 3C). When submitted to the Edman degradation 
procedure for amino acid sequencing, no amino acid was re- 
leased from the 100 kDa protein, indicating that the NH~- 
terminus was blocked. Therefore, a tryptic digestion of the 
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Fig. 3. Two-dimensional analysis of the purified TSP binding protein. The 100 kDa TSP binding component wasisolated from platelet cytosol by 
preparative electrophoresis, as described in section 2, and analyzed by two-dimensional O'Farrell electrophoresis. The purified protein (20 ~g)was 
subjected to isoelectrofocusing in the first dimension followed by electrophoresis on a SDS-6.5% polyacrylamide g l under reducing conditions in 
the second dimension. The protein was either stained with Coomassie blue (A) and subsequently with silver (B) or probed with 3/tg/ml [tzsI]TSP 
(C). 
protein was performed and two fractions collected from the 
HPLC chromatography of the hydrolysate were sequenced. 
Four short sequences were identified as part of the c~-actinin 
molecule: T(727)INEVENQILTR(738), E(85 I)LPPDQAEYX- 
IAR(863), L(566)AILGIHNEVSK(578) and I(835)LAGDKN- 
YITMDELR(849) [32]. 
3.4. [1251]TSP binding to solid-phase adsorbed purified c~-actinin 
A solid-phase binding assay was used to measure the affinity 
of the interaction of [125I]TSP with purified c~-actinin. When 
incubated with [12Sl]TSP over the range of 1.1 22 nM, immobi- 
lized ~-actinin was found to bind increasing amounts of 
[125I]TSP (Fig. 4A). By comparison, o binding of [125I]fibrino- 
gen or [J25I]fibronectin was measured. Non-specific binding of 
[~25I]TSP to ~-actinin amounted to 20 30% of the total binding; 
the specific binding was calculated and plotted following 
Scatchard analysis (Fig. 4B). A mean dissociation constant (Kd) 
of 6.6 nM was calculated from the data of two reproducible 
experiments. Finally, the binding of [~5I]TSP to solid-phase 
adsorbed c~-actinin was found to require the presence of diva- 
lent cations and to be inhibited by a monoclonal ntibody to 
c~-actinin used at 10/~g/ml (data not shown). 
4. Discussion 
The present s udy demonstrates for the first time a specific 
interaction of TSP with the cytoskeletal ctin binding protein, 
c~-actinin. The specificity of the interaction was demonstrated 
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Fig. 4. Specific interaction of ['~'SI]TSP with ~-actinin in a solid-phase 
binding assay. (A) Microtiter wells were coated in duplicate with 10 
pg/ml of purified ~-actinin and incubated with 1.1 22 nM [~-'5I]TSP (A), 
['>I]fibrinogen (=.) or [~:~l]fibronectin (e). In parallel samples, [~'51]TSP 
binding was measured in microtiter wells coated with BSA alone (x). 
Non-specific binding of [~2q]TSP to ~-actinin was measured in the 
presence of excess (60x) unlabeled TSP (e). (B) Specific binding of 
[~>I]TSP to ~-actinin was calculated by subtracting non-specific bind- 
ing from the total binding: the Scatchard plot is shown in the inset. 
in a solid-phase binding assay: (i) binding of [~eSI]TSP to ~- 
actinin was concentration-dependent and saturable; (ii) excess 
of unlabeled TSP inhibited this binding by 70 80%; (iii) the 
binding was specifically inhibited by a monoclonal antibody to 
a-actinin: and (iv) two other a-granular adhesive proteins, 
namely [~25I]fibrinogen a d [~2sI]fibronectin, failed to interact 
with ~-actinin by this technique. 
Using a blot binding assay performed with whole platelet 
proteins, [12Sl]TSP was bound almost exclusively to a-actinin. 
Other platelet proteins, including fibronectin, histidine-rich 
glycoprotein, plasminogen and GPIV were undetectable al- 
though they were previously shown, in the purified form, to 
interact with TSP by the blot binding technique [5,33]. Our 
failure to detect hese proteins may be due to their low concen- 
trations in platelets. The weak reactivity observed with fibrino- 
gen, which is abundant in platelets, as compared to a-actinin, 
demonstrates a higher affinity of TSP for a-actimn. Indeed, 
from the results obtained in the solid-phase binding assay, we 
measured a dissociation constant of 6.6 nM for the TSPa-  
actinin interaction in comparison to 40 nM for the interaction 
of TSP with fibrinogen under similar conditions (personal re- 
suits). 
An association between secreted adhesive a-granular pro- 
teins and the cytoskeleton is currently thought o be mediated 
by transmembrane proteins, such as integrins, acting as recep- 
tors for the adhesive proteins [34]. The present demonstration 
of a direct association of the a-granular protein TSP with the 
cytoskeletal protein a-actinin raises the question of when do 
these two proteins have an opportunity to interact with each 
other in a cellular context. The presence of a-actinin in the 
~-granules of resting platelets was already evidenced by an 
immunoelectron microscopic study [35]. In addition, upon 
platelet activation by thrombin, a-actinin was found to be redis- 
tributed towards the plasma membrane [36,37]. We have also 
addressed this point by comparing the localization of a-actinin 
and TSP in platelets. By performing indirect immunofluores- 
cence studies on resting platelets we confirmed the cytosolic 
localization of ~-actinin shown by others [36,37]. However, 
additional staining of ~-actinin with a distribution similar to 
that of TSP was also observed, suggesting a possible co-localiz- 
ation of these two proteins in the a-granules (manuscript in 
preparation). This is compatible with the results obtained by 
platelet subfractionation (Fig. 2) showing a fraction of ~-ac- 
tinin in the granular-enriched subfraction. Further studies are 
needed to investigate the physiological significance of the inter- 
action between TSP and c~-actinin during the platelet activation 
process. 
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